Patents Examined by Amanda L Aguirre
  • Patent number: 10323045
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: June 18, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: George Hynd, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, John Gary Montana, Stephen Colin Price
  • Patent number: 10315992
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 11, 2019
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Patent number: 10316026
    Abstract: In a method for producing a de-dimethoxybenzylated compound by removing a dimethoxybenzyl group from a compound containing a dimethoxybenzyl group bonded to a nitrogen atom in the presence of an acid, the de-dimethoxybenzylated compound is obtained by removing the dimethoxybenzyl group without forming a poorly soluble product resulting from the removed dimethoxybenzyl group. The de-dimethoxybenzylation reaction is carried out in the presence of triphenylphosphine or diethylthiourea.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 11, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kohei Kadota, Tsuyoshi Ueda
  • Patent number: 10316013
    Abstract: Disclosed is an organic light emitting compound represented by Formula I: Also disclosed is an organic light emitting device including the organic light emitting compound. The organic light emitting device can be driven at a low voltage to achieve high power efficiency. In addition, the organic light emitting device has excellent luminescent properties, such as high luminance and high luminous efficiency. Due to these advantages, the organic light emitting device can be utilized as a display device or a lighting device.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 11, 2019
    Assignee: SFC Co., Ltd.
    Inventors: Jeong-Soo Kim, Yeon-kwon Ryu, Sang-Won Ko, Su-Jin Lee, Ji-Hwan Kim, Ji-young Kim
  • Patent number: 10312456
    Abstract: The invention relates to a composition having an organic emitter molecule, which has a ?E(S1?T1) value between the lowest excited singlet state (S1) and the triplet state thereunder of less than 3000 cm?1 and an atom or molecule for reducing the intersystem crossing time constant of the organic molecule.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: June 4, 2019
    Assignee: CYNORA GMBH
    Inventors: Hartmut Yersin, Alexander Hupfer
  • Patent number: 10301269
    Abstract: The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: May 28, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Patent number: 10301255
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 28, 2019
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yao-Ling Qiu, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xuri Gao, Xiaowen Peng, Yat Sun Or
  • Patent number: 10287227
    Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: May 14, 2019
    Assignees: UNIVERSITY OF SOUTH FLORIDA, The Department of Veterans Affairs
    Inventors: Chad Dickey, Umesh Jinwal, Laurent Calcul, Bill J. Baker, Matthew Lebar
  • Patent number: 10287254
    Abstract: The invention relates to besylate and tosylate salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl} acetic acid and solvates thereof, to the use thereof in a method of treating and/or preventing virus infections, and to the use thereof to produce drugs for use in treating and/or preventing diseases, in particular use as antiviral agents, in particular against cytomegaloviruses (FIG. 1).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: May 14, 2019
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Welljanne Maertens, Christian Schickaneder
  • Patent number: 10273208
    Abstract: Disclosed are methods for preparing and screening for an inhibitor of the activity of a biological molecule having a catalytic or non-catalytic cysteine residue. The methods including preparing a library of candidate inhibitor molecules by conjugating an electrophile to a plurality of drug molecules where the library of candidate inhibitor molecules thus formed react with cysteine residues. The library of candidate inhibitor molecules then may be reacted with the biological molecule to identify those inhibitor molecule that react with the catalytic or non-catalytic cysteine residue of the biological molecule in order to identify an inhibitor of the biological molecule.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: April 30, 2019
    Assignee: Northwestern University
    Inventors: Alexander V. Statsyuk, Stefan G. Kathman
  • Patent number: 10273252
    Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 30, 2019
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Noriaki Iwase, Yasuhiro Aga, Shigeru Ushiyama, Shigeyuki Kono, Hidetoshi Sunamoto, Takashi Matsushita, Sayaka Ogi, Satoshi Umezaki, Masahiro Kojima, Kazuhiro Onuma, Yusuke Shiraishi, Makoto Okudo, Tomio Kimura
  • Patent number: 10266547
    Abstract: The present invention relates to a novel class of alkylating agents comprising a thieno[2,3-e]indole moiety tethered to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 23, 2019
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Marina Caldarelli, Michele Caruso, Paolo Orsini
  • Patent number: 10266521
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 23, 2019
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
  • Patent number: 10265411
    Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 23, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Patent number: 10266481
    Abstract: The present invention relates to a short enantioselective synthesis of 1-amino aryl tetraline compounds of Formula 1 via nucleophilic enamine catalysis using organocatalyst such as proline. wherein R1 and R2 represent independent of each other hydrogen, (un)substituted or substituted amine; R3 and R4 represent independent of each other hydrogen or halogen.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: April 23, 2019
    Assignee: Council of Scientific & Industrial Research
    Inventors: Venkataramasubramanian Vaithiyanathan, Rupali Gundappa Kalshetti, Sudalai Arumugam
  • Patent number: 10246421
    Abstract: The invention relates to indazolylbenzamide, indolylbenzamide, benzo[d]imidazolyl-benzamide, and benzo[d]triazolylbenzamide derivatives of formula useful in the treatment and/or prevention of diseases and/or conditions related to cell proliferation, such as cancer, infection, inflammation and inflammation-associated disorders, and conditions associated with angiogenesis.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 2, 2019
    Assignee: Esanex, Inc.
    Inventor: Philip F. Hughes
  • Patent number: 10233165
    Abstract: The present disclosure relates to cyclopropyl compounds of general formula (I), wherein R1, and R2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: March 19, 2019
    Assignee: Istituto Europeo di Oncologia S.r.l.
    Inventors: Paola Vianello, Mario Varasi, Ciro Mercurio, Anna Cappa, Giuseppe Meroni, Manuela Villa, Antonello Mai, Sergio Valente
  • Patent number: 10221167
    Abstract: Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas J. Greshock, James Mulhearn, Junying Zheng, Ronald M. Kim, Ting Zhang, Anthony J. Roecker, Walter Won, Philippe Nantermet, Rajan Anand, Gang Zhou, Deping Wang, Liangqin Guo
  • Patent number: 10213415
    Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 26, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
  • Patent number: 10214537
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: February 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Douglas G. Batt, Robert J. Cherney, Lyndon A. M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson